颌骨放射性骨坏死诊断标准在放疗并骨改良药物暴露癌症患者中的评估
结果显示仅原发头颈癌患者坏死部位最大平均剂量达放射性骨坏死(ORN)范围(>40 Gy),按修改标准近2/3原诊为ORN者应诊为药物相关性颌骨坏死(MRONJ)。结论建议ORN诊断仅考虑放疗暴露>40 Gy,并推荐修改MRONJ诊断标准纳入坏死部位放疗<40 Gy。
要点
- ORN诊断应仅考虑颌骨坏死部位放疗暴露>40 Gy,以避免误诊和治疗不当。
- 修改标准后近2/3原诊为ORN的病例应改诊为MRONJ。
- 建议修改MRONJ诊断标准,纳入坏死部位放疗暴露<40 Gy。
核心结论
- ORN诊断应仅考虑放疗暴露>40 Gy,以避免误诊和次优治疗。
- 推荐修改MRONJ诊断标准,纳入坏死部位放疗暴露<40 Gy。
- 放疗暴露>40 Gy且使用骨改良药物(BMA)时,应使用「药物和放疗相关性颌骨坏死」的额外修改诊断标准。
研究设计与样本
- 使用修改后的诊断标准重新评估所有病例,并采用Pearson卡方/Fisher精确检验比较结果。
主要发现
- 仅原发头颈癌患者坏死颌骨部位最大平均放疗剂量达到与ORN形成相关的范围(>40 Gy),个别病例暴露低至0-2 Gy。
- 基于修改后的诊断标准,近2/3诊断为ORN的坏死病例应诊断为MRONJ。
关键数值与推荐
- ORN形成相关的最大平均放疗剂量范围>40 Gy。
- 修改标准后近2/3原诊为ORN的病例应改诊为MRONJ。
- 推荐修改MRONJ诊断标准纳入坏死部位放疗暴露<40 Gy。
- 放疗暴露>40 Gy且使用BMA时,推荐使用「药物和放疗相关性颌骨坏死」的诊断标准修改。
临床怎么用
- 颌骨坏死诊断时应计算坏死部位最大放疗剂量,仅放疗暴露>40 Gy才考虑ORN。
- 坏死部位放疗暴露<40 Gy且有BMA暴露时,应按修改标准考虑MRONJ。
- 放疗暴露>40 Gy且使用BMA时,应使用「药物和放疗相关性颌骨坏死」诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoradionecrosis (ORN) of the jaw is currently defined by the development of osteonecrosis in head/neck irradiated patients, regardless of lesion exposure. To diagnose medication-related osteonecrosis of the jaw (MRONJ), a history of any radiation therapy to the jaw region must be ruled out. The aim of this study was to assess the accuracy of current osteonecrosis criteria, while introducing new modifications for improved diagnosis and treatment. METHODS: One hundred and forty-one necrotic lesions were analyzed from patients exposed to bone-modifying agents (BMAs) and/or received head and neck regional radiation therapy, where the maximal dose of radiation exposure to the jaw osteonecrosis site was calculated. Modified diagnostic criteria were used to reassess all cases and a comparison of outcomes was performed using Pearson's Chi-Square/Fisher's exact test. RESULTS: Only in patients with primary head and neck carcinomas did the maximal mean radiation dose in the necrotic jaw site reach ranges associated with ORN formation (>40 Gy), with individual cases showing exposures as low as 0-2 Gy. Based on the modified diagnostic criteria almost 2/3 of the necrotic cases diagnosed as ORN should be diagnosed as MRONJ. CONCLUSIONS: ORN diagnosis should only be considered in cases of radiation exposure >40 Gy to prevent misdiagnosis and suboptimal treatment. A modified criterion for MRONJ diagnosis is recommended where radiation exposure <40 Gy in the necrotic site is included. In cases with exposure >40 Gy and BMA administration, an additional modification to diagnostic criteria of 'medication- and radiation-related osteonecrosis of the jaw', should be used.
引用
- Zadik Y, Ganor Y, Rimon O, et al. Assessment of jaw osteonecrosis diagnostic criteria in cancer patients with a history of radiation therapy and exposure to bone-modifying agents. Radiother Oncol. 2020. PMID: 33373641. doi:10.1016/j.radonc.2020.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。